Incyte (INCY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Incyte Revenue Highlights

Latest Revenue (Y)

$4.24B

Latest Revenue (Q)

$962.99M

Main Segment (Y)

J A K A F I

Main Geography (Y)

U [S]

Incyte Revenue by Period

Incyte Revenue by Year

Date	Revenue	Change
2024-12-31	$4.24B	14.76%
2023-12-31	$3.70B	8.87%
2022-12-31	$3.39B	13.67%
2021-12-31	$2.99B	11.98%
2020-12-31	$2.67B	23.53%
2019-12-31	$2.16B	14.71%
2018-12-31	$1.88B	22.50%
2017-12-31	$1.54B	38.93%
2016-12-31	$1.11B	46.70%
2015-12-31	$753.75M	47.36%
2014-12-31	$511.50M	44.10%
2013-12-31	$354.95M	19.49%
2012-12-31	$297.06M	214.50%
2011-12-31	$94.45M	-44.40%
2010-12-31	$169.88M	1733.55%
2009-12-31	$9.27M	136.41%
2008-12-31	$3.92M	-88.62%
2007-12-31	$34.44M	24.59%
2006-12-31	$27.64M	252.32%
2005-12-31	$7.85M	-44.54%
2004-12-31	$14.15M	-69.96%
2003-12-31	$47.09M	-53.66%
2002-12-31	$101.61M	-53.66%
2001-12-31	$219.26M	12.92%
2000-12-31	$194.17M	23.67%
1999-12-31	$157.00M	16.47%
1998-12-31	$134.80M	52.49%
1997-12-31	$88.40M	111.48%
1996-12-31	$41.80M	242.62%
1995-12-31	$12.20M	6000.00%
1994-12-31	$200.00K	-33.33%
1993-12-31	$300.00K	-

Incyte generated $4.24B in revenue during NA 2024, up 14.76% compared to the previous quarter, and up 196.47% compared to the same period a year ago.

Incyte Revenue by Quarter

Date	Revenue	Change
2024-09-30	$962.99M	-7.74%
2024-06-30	$1.04B	18.49%
2024-03-31	$880.89M	-13.07%
2023-12-31	$1.01B	10.26%
2023-09-30	$919.02M	-3.73%
2023-06-30	$954.61M	18.05%
2023-03-31	$808.67M	-12.74%
2022-12-31	$926.70M	12.56%
2022-09-30	$823.30M	-9.67%
2022-06-30	$911.40M	24.30%
2022-03-31	$733.24M	-15.02%
2021-12-31	$862.85M	6.13%
2021-09-30	$812.99M	15.20%
2021-06-30	$705.71M	16.70%
2021-03-31	$604.72M	-23.41%
2020-12-31	$789.51M	27.21%
2020-09-30	$620.64M	-9.80%
2020-06-30	$688.04M	21.03%
2020-03-31	$568.51M	-1.88%
2019-12-31	$579.39M	5.04%
2019-09-30	$551.58M	4.09%
2019-06-30	$529.93M	6.44%
2019-03-31	$497.86M	-5.78%
2018-12-31	$528.40M	17.51%
2018-09-30	$449.68M	-13.77%
2018-06-30	$521.52M	36.42%
2018-03-31	$382.28M	-13.93%
2017-12-31	$444.16M	16.41%
2017-09-30	$381.53M	16.88%
2017-06-30	$326.44M	-15.01%
2017-03-31	$384.08M	17.64%
2016-12-31	$326.50M	21.16%
2016-09-30	$269.47M	9.41%
2016-06-30	$246.29M	-6.52%
2016-03-31	$263.46M	8.03%
2015-12-31	$243.88M	29.99%
2015-09-30	$187.61M	15.11%
2015-06-30	$162.98M	2.33%
2015-03-31	$159.28M	28.48%
2014-12-31	$123.97M	-37.43%
2014-09-30	$198.15M	98.98%
2014-06-30	$99.58M	10.90%
2014-03-31	$89.79M	-7.50%
2013-12-31	$97.07M	14.04%
2013-09-30	$85.12M	-16.28%
2013-06-30	$101.67M	43.05%
2013-03-31	$71.08M	-37.57%
2012-12-31	$113.85M	88.20%
2012-09-30	$60.49M	-30.10%
2012-06-30	$86.54M	139.21%
2012-03-31	$36.18M	25.23%
2011-12-31	$28.89M	72.15%
2011-09-30	$16.78M	-0.17%
2011-06-30	$16.81M	-47.42%
2011-03-31	$31.97M	-62.77%
2010-12-31	$85.87M	408.95%
2010-09-30	$16.87M	-66.15%
2010-06-30	$49.85M	188.33%
2010-03-31	$17.29M	151.79%
2009-12-31	$6.87M	631.20%
2009-09-30	$939.00K	19.01%
2009-06-30	$789.00K	17.59%
2009-03-31	$671.00K	-28.46%
2008-12-31	$938.00K	-11.59%
2008-09-30	$1.06M	72.80%
2008-06-30	$614.00K	-53.02%
2008-03-31	$1.31M	-

Incyte generated $962.99M in revenue during Q3 2024, up -7.74% compared to the previous quarter, and up 100.88% compared to the same period a year ago.

Incyte Revenue Breakdown

Incyte Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Olumiant Royalty	$135.57M	$134.55M	$110.92M	$80.42M	-
Milestone And Contract Revenue	$43.00M	$165.00M	$205.00M	$77.50M	-
M I N J U V I	$119.24M	$19.65M	-	-	-
J A K A F I	$3.21B	$2.74B	-	-	-
I C L U S I G	$114.32M	$105.84M	$105.00M	$89.95M	-
Tabrecta Royalty Revenues	$22.75M	$15.41M	$4.14M	-	-
PEMAZYRE Royalty Revenues	$83.92M	$84.65M	-	-	-
ZYNYZ	$3.19M	-	-	-	-
OPZELURA	$508.29M	$128.74M	$4.91M	-	-
Milestone and contract revenues	-	$165.00M	$95.00M	-	-
Product	-	$2.75B	$2.07B	$1.77B	-
Royalty	-	$482.74M	$392.97M	$306.34M	-
ICLUSIG	-	-	$4.67M	-	-
Product revenues, net	-	-	$2.32B	-	-
Product royalty revenues	-	-	$569.25M	-	-
TABRECTA Royalty Revenues	-	-	$10.39M	-	-
PEMAZYRE	-	-	$109.39M	-	-
OLUMIANT Royalty Revenues	-	-	$220.88M	-	-
MINJUVI	-	-	$68.53M	-	-
JAKAVI Royalty Revenues	-	-	$337.99M	-	-
Jakavi Royalty Revenues	-	-	-	$277.90M	$225.91M
Pemazyre	-	-	-	$25.88M	-

Incyte's latest annual revenue breakdown by segment (product or service), as of Dec 24: J A K A F I (75.71%), OPZELURA (11.98%), Olumiant Royalty (3.20%), M I N J U V I (2.81%), I C L U S I G (2.70%), PEMAZYRE Royalty Revenues (1.98%), Milestone And Contract Revenue (1.01%), Tabrecta Royalty Revenues (0.54%), and ZYNYZ (0.08%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
M I N J U V I	$32.81M	$31.44M	$31.12M	$23.87M	$556.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
J A K A F I	$2.91B	$115.74M	$99.32M	$89.59M	$547.37M	$529.05M	$465.71M	$516.88M	$487.78M	$473.71M	$459.48M	$466.46M	-	-	-	-	-	-	-	-
I C L U S I G	$27.37M	$29.75M	$26.86M	$30.34M	$28.52M	$28.19M	$25.64M	$28.58M	$26.38M	$22.80M	$27.25M	$24.31M	-	-	-	-	-	-	-	-
Tabrecta Royalty Revenues	$6.29M	$5.93M	$5.30M	$5.23M	$2.75M	$2.48M	$2.05M	$2.00M	$1.44M	$706.00K	-	-	-	-	-	-	-	-	-	-
PEMAZYRE Royalty Revenues	$23.48M	$21.07M	$21.14M	$18.22M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ZYNYZ	$1.37M	$694.00K	$651.00K	$467.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Milestone And Contract Revenue	-	$18.00M	-	$25.00M	$35.00M	$10.00M	$110.00M	-	$95.00M	-	-	-	-	-	-	-	-	-	-	-
Olumiant Royalty	$38.48M	$34.80M	$31.70M	$30.59M	$86.57M	$36.05M	$32.26M	$31.00M	$28.65M	$25.83M	$25.45M	$23.60M	-	-	-	-	-	-	-	-
OPZELURA	$161.60M	$139.27M	$121.69M	$85.72M	$91.84M	$80.23M	$56.55M	$38.14M	$16.56M	$12.75M	-	-	-	-	-	-	-	-	-	-
JAKAVI Royalty Revenues	-	-	-	$89.59M	$96.55M	$90.45M	$76.69M	$85.81M	$83.71M	$70.87M	$95.70M	-	-	-	-	-	-	-	-	-
ICLUSIG	-	-	-	$30.34M	$27.72M	$29.09M	$27.68M	$25.93M	$26.22M	$26.07M	$-77.69M	-	-	-	-	-	-	-	-	-
PEMAZYRE	-	-	-	$17.68M	$18.94M	$21.57M	$22.48M	$23.41M	$18.98M	$18.03M	$60.47M	-	-	-	-	-	-	-	-	-
OLUMIANT Royalty Revenues	-	-	-	$30.59M	$29.61M	$32.01M	$34.16M	$20.37M	$66.00M	-	-	-	-	-	-	-	-	-	-	-
Milestone and contract revenues	-	-	-	$25.00M	-	$5.00M	$50.00M	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	-	-	$729.92M	$783.20M	$827.00M	$693.24M	$713.01M	$594.01M	$575.15M	$504.81M	$559.47M	$522.25M	$500.29M	$486.73M	$490.78M	-	-	-	-
Royalty	-	-	-	$125.97M	$130.83M	$127.61M	$115.44M	$110.29M	$183.97M	$120.56M	$99.91M	$120.04M	$98.39M	$92.75M	$81.78M	$88.61M	-	-	-	-
TABRECTA Royalty Revenues	-	-	-	$5.23M	$4.14M	$4.80M	$4.18M	$4.11M	$3.58M	$3.48M	$3.12M	-	-	-	-	-	-	-	-	-
JAKAFI	-	-	-	-	$636.25M	$682.38M	$579.97M	$647.49M	$619.60M	$597.67M	$544.46M	$592.37M	-	-	-	-	-	-	-	-
MINJUVI	-	-	-	-	$8.35M	$13.16M	$6.56M	$5.93M	$4.41M	$4.50M	$67.97M	-	-	-	-	-	-	-	-	-
Product revenues, net	-	-	-	-	-	-	-	-	-	$663.85M	$605.82M	$648.04M	-	-	-	-	-	-	-	-
Product royalty revenues	-	-	-	-	-	-	-	-	-	$117.55M	$122.41M	$164.81M	-	-	-	-	-	-	-	-
Jakavi Royalty Revenues	-	-	-	-	-	-	-	-	-	-	-	-	$94.66M	$82.04M	$65.60M	$87.05M	$68.31M	$66.22M	$56.33M	$65.01M
Pemazyre	-	-	-	-	-	-	-	-	-	-	-	-	$17.56M	$17.91M	$13.46M	$14.01M	$8.09M	$3.79M	-	-
Milestone Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Incyte's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: J A K A F I (90.89%), OPZELURA (5.05%), Olumiant Royalty (1.20%), M I N J U V I (1.03%), I C L U S I G (0.86%), PEMAZYRE Royalty Revenues (0.73%), Tabrecta Royalty Revenues (0.20%), and ZYNYZ (0.04%).

Incyte Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
U [S]	$4.00B	-	-	-	-
Europe	$260.40M	$147.00M	$124.10M	$105.00M	$90.00M
UNITED STATES	-	$3.20B	-	-	-
U.S.	-	-	$2.90B	-	-
U	-	-	-	$2.60B	$2.10B

Incyte's latest annual revenue breakdown by geography, as of Dec 24: U [S] (93.89%), and Europe (6.11%).

Quarterly Revenue by Country

Country	Dec 19	Dec 18
Non Us	$88.60M	$69.20M

Incyte's latest quarterly revenue breakdown by geography, as of Dec 19: Non Us (100.00%).

Incyte Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$4.24B	$962.99M
UTHR	United Therapeutics	$2.88B	$748.90M
BMRN	BioMarin Pharmaceutical	$2.85B	$733.87B
BGNE	BeiGene	$2.46B	$929.17M
ALNY	Alnylam Pharmaceuticals	$2.25B	$420.15M
SRPT	Sarepta Therapeutics	$1.90B	$362.93M
ARGX	argenx SE	$1.23B	$401.00M
ACAD	ACADIA Pharmaceuticals	$957.80M	$250.40M
HRMY	Harmony Biosciences	$714.73M	$186.04M
APLS	Apellis Pharmaceuticals	$709.95M	$176.57M
IONS	Ionis Pharmaceuticals	$705.14M	$225.25M
RARE	Ultragenyx Pharmaceutical	$560.23M	$147.03M
FOLD	Amicus Therapeutics	$528.29M	$141.52M
AXSM	Axsome Therapeutics	$385.69M	$87.17M
ARWR	Arrowhead Pharmaceuticals	$3.55M	$2.50M
DNLI	Denali Therapeutics	-	-

INCY Revenue FAQ

What is Incyte’s yearly revenue?

Incyte's yearly revenue for 2024 was $4.24B, representing an increase of 14.76% compared to 2023. The company's yearly revenue for 2023 was $3.7B, representing an increase of 8.87% compared to 2022. INCY's yearly revenue for 2022 was $3.39B, representing an increase of 13.67% compared to 2021.

What is Incyte’s quarterly revenue?

Incyte's quarterly revenue for Q3 2024 was $962.99M, a -7.74% decrease from the previous quarter (Q2 2024), and a 4.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.04B, a 18.49% increase from the previous quarter (Q1 2024), and a 9.34% increase year-over-year (Q2 2023). INCY's quarterly revenue for Q1 2024 was $880.89M, a -13.07% decrease from the previous quarter (Q4 2023), and a 8.93% increase year-over-year (Q1 2023).

What is Incyte’s revenue growth rate?

Incyte's revenue growth rate for the last 3 years (2022-2024) was 24.94%, and for the last 5 years (2020-2024) was 59.04%.

What are Incyte’s revenue streams?

Incyte's revenue streams in c 24 are Olumiant Royalty, Milestone And Contract Revenue, M I N J U V I, J A K A F I, I C L U S I G, Tabrecta Royalty Revenues, PEMAZYRE Royalty Revenues, ZYNYZ, and OPZELURA. Olumiant Royalty generated $135.57M in revenue, accounting 3.20% of the company's total revenue, up 0.76% year-over-year. Milestone And Contract Revenue generated $43M in revenue, accounting 1.01% of the company's total revenue, down -73.94% year-over-year. M I N J U V I generated $119.24M in revenue, accounting 2.81% of the company's total revenue, up 506.68% year-over-year. J A K A F I generated $3.21B in revenue, accounting 75.71% of the company's total revenue, up 17.15% year-over-year. I C L U S I G generated $114.32M in revenue, accounting 2.70% of the company's total revenue, up 8.01% year-over-year. Tabrecta Royalty Revenues generated $22.75M in revenue, accounting 0.54% of the company's total revenue, up 47.60% year-over-year. PEMAZYRE Royalty Revenues generated $83.92M in revenue, accounting 1.98% of the company's total revenue, down -0.86% year-over-year. ZYNYZ generated $3.18M in revenue, accounting 0.08% of the company's total revenue OPZELURA generated $508.29M in revenue, accounting 11.98% of the company's total revenue, up 294.84% year-over-year.

What is Incyte’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Incyte was J A K A F I. This segment made a revenue of $3.21B, representing 75.71% of the company's total revenue.